Skip to content
Other

Equity method investment, impairment

Constellation Brands Equity method investment, impairment decreased by 100.0% to $0 in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $300K to $0. Over 2 years (FY 2023 to FY 2025), Equity method investment, impairment shows a downward trend with a -90.9% CAGR.

Analysis

StatementIncome Statement
SectionOther
First reportedQ1 2021
Last reportedQ3 2026Jan 8, 2026
Metric ID: other_equity_method_investment_other_than_temporary_impairment

Historical Data

16 periods
 Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q2 '26Q3 '26
Value$0$0$0$1.06B$0$0$123.5M$12.3M$300K$0$0$2.1M$300K$6.3M$1.5M$0
QoQ Change-100.0%-90.0%-97.6%-100.0%-85.7%>999%-76.2%-100.0%
YoY Change-98.8%-100.0%-82.9%+0.0%-28.6%-100.0%
Range$0$1.06B
Avg YoY Growth-68.4%
Median YoY Growth-90.9%
Current Streak2 quarters decline

Frequently Asked Questions

What is Constellation Brands's equity method investment, impairment?
Constellation Brands (STZ) reported equity method investment, impairment of $0 in Q3 2025.
How has Constellation Brands's equity method investment, impairment changed year-over-year?
Constellation Brands's equity method investment, impairment decreased by 100.0% year-over-year, from $300K to $0.
What is the long-term trend for Constellation Brands's equity method investment, impairment?
Over 2 years (2023 to 2025), Constellation Brands's equity method investment, impairment has grown at a -90.9% compound annual growth rate (CAGR), from $1.06B to $8.7M.